Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, WTX101 (bis-choline-tetrathiomolybdate), is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been successfully completed and preparations for a pivotal Phase 3 study are ongoing.

Wilson Therapeutics AB was founded in 2012 and is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.